Selinexor (KPT-330) in Older Patients With Relapsed AML (SOPRA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02088541|
Recruitment Status : Completed
First Posted : March 17, 2014
Last Update Posted : April 1, 2019
|Condition or disease||Intervention/treatment||Phase|
|Acute Myeloid Leukemia (AML)||Drug: Selinexor Drug: Hydroxyurea Drug: Ara-C Drug: Azacitidine Drug: Decitabine||Phase 2|
This is a randomized, multicenter, open-label phase 2 study of the SINE compound, selinexor given orally versus restricted investigator choice (i.e., one of three potential salvage therapies).
Patients who have never been transplant eligible, are currently deemed unfit for intensive chemotherapy, ≥ 60 years old, who have AML (except Acute Promyelocytic Leukemia: APL, AML M3) after one prior treatment of either hypomethylating agent or a regimen including Ara-C, and are meeting the inclusion and exclusion criteria will be randomized to receive either oral selinexor or physician's choice (one of three potential treatments: best supportive care (BSC) alone, or BSC + hypomethylating agent, or BSC + low dose Ara-C until disease progression, death or intolerance has occurred.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||171 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (Sine) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation|
|Study Start Date :||March 2014|
|Actual Primary Completion Date :||January 8, 2018|
|Actual Study Completion Date :||January 8, 2018|
Experimental: Selinexor (KPT-330)
20 mg oral tablets
Other Name: KPT-330
Active Comparator: Physician's Choice
One of the following 3 conventional care regimens will be selected by the physician:
Other Name: Hydroxycarbamide
- Overall survival [ Time Frame: From the date of randomization until the date of death, or study end (up to approximately 104 weeks) ]To determine overall survival (OS) of Selinexor as compared to physician choice (PC).
- 3 month survival [ Time Frame: up to 3 months ]Survival at 3 months post-randomization
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02088541
|Study Director:||Michael Kauffman, MD, PhD||Karyopharm Therapeutics Inc|